Lipomedix Pharmaceuticals Ltd
Dr. Patricia Ohana brings to LipoMedix over 20 years of experience and successful record in translating a product from pre-clinical to clinical stage in the development of anti-cancer drugs. Prior to joining LipoMedix, Dr. Ohana most recently served as the Vice President of Research and Development and earlier, the Vice President of Clinical Development of BioCancell a biotech company dedicated to the development of DNA based drugs for the treatment of cancer. There she directed the development of their therapeutic product into multinational clinical trials. She previously held a position as research scientist in the Department of Biological Chemistry at the Hebrew University where she had a key role in the development of BC-819 as a drug for the treatment of cancer.